HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead’s twice-a-year PrEP medication lenacapavir, prompting…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Encoded secures $275m for Dravet syndrome gene therapy
Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for…
-
Podcast: key readouts from ESC and ERS
It's conference season again. In this episode, the healthcare team rounds up the latest readouts and emerging themes from two…
-
“Unparalleled opportunity”: Sandoz embarks on ambitious biosimilar growth strategy
This year, Sandoz celebrated the 20th anniversary of its – and the world's – first marketed biosimilar. But instead of…
-
Quoin in line for priority review voucher if rare paediatric drug approved
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Quoin Pharmaceuticals’ candidate in development for…
-
EU pharma industry pushes for expansion of barcodes on medicines
Two European pharmaceutical trade associations have called for the wider application of barcodes to include individual dose identification. New guidance…
-
Pineapples and green tea: FDA turns to public for new approaches to botanical drugs
The US Food and Drug Administration (FDA) is requesting public input on both the opportunities and challenges regarding drugs derived…
-
GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal
GSK will pay a subsidiary of HUTCHMED $110m upfront for a novel type of drug designed to selectively target solid…
-
Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn
Roche is outlaying $1.53bn for the global rights to Simcere Zaiming’s trispecific antibody targeting B-cell-mediated diseases, marking the second time…
-
Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal
Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease…